Abstract
BackgroundMetabolomics is a tool that has been used for the diagnosis and prognosis of specific diseases. The purpose of this study was to examine if metabolomics could be used as a potential diagnostic and prognostic tool for H1N1 pneumonia. Our hypothesis was that metabolomics can potentially be used early for the diagnosis and prognosis of H1N1 influenza pneumonia.Methods1H nuclear magnetic resonance spectroscopy and gas chromatography-mass spectrometry were used to profile the metabolome in 42 patients with H1N1 pneumonia, 31 ventilated control subjects in the intensive care unit (ICU), and 30 culture-positive plasma samples from patients with bacterial community-acquired pneumonia drawn within the first 24 h of hospital admission for diagnosis and prognosis of disease.ResultsWe found that plasma-based metabolomics from samples taken within 24 h of hospital admission can be used to discriminate H1N1 pneumonia from bacterial pneumonia and nonsurvivors from survivors of H1N1 pneumonia. Moreover, metabolomics is a highly sensitive and specific tool for the 90-day prognosis of mortality in H1N1 pneumonia.ConclusionsThis study demonstrates that H1N1 pneumonia can create a quite different plasma metabolic profile from bacterial culture-positive pneumonia and ventilated control subjects in the ICU on the basis of plasma samples taken within 24 h of hospital/ICU admission, early in the course of disease.
Highlights
Metabolomics is a tool that has been used for the diagnosis and prognosis of specific diseases
Diagnosis of H1N1 pneumonia based on a ventilated intensive care unit (ICU) control population and patients with culture-positive bacterial community-acquired pneumonia (CAP) To assess the value of plasma metabolomics for the diagnosis of H1N1 pneumonia, patients with H1N1 pneumonia, ventilated ICU control subjects, and patients with CAP with positive bacterial cultures were used to explore and create prediction models based on 29 patients with H1N1 pneumonia vs. 29 sex-matched patients with CAP with positive bacterial cultures and based on 42 patients with H1N1 pneumonia vs. 31 age- and sex-matched ventilated ICU control subjects (Table 1)
These data show that plasma metabolomics using Proton nuclear magnetic resonance (1H-NMR) and gas chromatography-mass spectrometry (GC-MS) analytical platforms could be applied as a diagnostic tool with high predictability, sensitivity, and specificity for identification of H1N1 influenza pneumonia
Summary
Metabolomics is a tool that has been used for the diagnosis and prognosis of specific diseases. Our hypothesis was that metabolomics can potentially be used early for the diagnosis and prognosis of H1N1 influenza pneumonia. Methods: 1H nuclear magnetic resonance spectroscopy and gas chromatography-mass spectrometry were used to profile the metabolome in 42 patients with H1N1 pneumonia, 31 ventilated control subjects in the intensive care unit (ICU), and 30 culture-positive plasma samples from patients with bacterial community-acquired pneumonia drawn within the first 24 h of hospital admission for diagnosis and prognosis of disease. The case fatality rate of influenza pneumonia in adults can reach up to 30% in the intensive care unit (ICU). 13% to 45.3% of hospitalized patients with influenza pneumonia are admitted to the ICU [5].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
